The new pharmaceutical compositions contain, apart from one or more active ingredient(s), between 0.01 and 60% w/w of the compounds of formula I ##STR00001##
with n and m>18 and <46 and with molecular weights between ˜600 and ˜8000 for the enhancement of absorption of the active ingredient(s). Moreover, such compositions may contain also between 0.01 and 20% w/w of Phosphatidylcholine.

Patent
   7026360
Priority
Feb 18 1999
Filed
Feb 16 2000
Issued
Apr 11 2006
Expiry
Feb 16 2020
Assg.orig
Entity
Small
31
6
EXPIRED
1. A pharmaceutical composition comprising, in addition to one or more pharmacologically active ingredient, wherein the active ingredient is Troxerutine, Nimesulide, or a nonsteroidal anti-inflammatory drug, wherein said non-steroidal anti-inflammatory drug is Ketoprofen, Diclofenac Sodium, Ibuprofen, Etodolic Acid, Piroxicam, or a combination thereof,
between 0.01 percent and 60 percent by weight of a compound of formula I ##STR00007##
with n and m>18 and <46 and with a molecular weight between about 600 and about 18,000, in combination with 0.01% to 20% by weight of phosphatidylcholine, for enhancement of active-ingredient absorption.
15. A pharmaceutical composition consisting essentially of
(1) one or more pharmacologically active ingredient, wherein the active ingredient is Troxerutine, Nimesulide, or a nonsteroidal anti-inflammatory drug, wherein said non-steroidal anti-inflammatory drug is Ketoprofen, Diclofenac Sodium, Ibuprofen, Etodolic Acid, Piroxicam, or a combination thereof;
(2) between about 0.01 percent and about 60 percent by weight of a compound of formula I ##STR00008##
wherein n and m are each greater than 18 and are each less than 46 and wherein the compound of the formula I has a molecular weight between about 600 and about 8,000;
(3) phosphatidylcholine;
(4) optionally tocopherol acetate;
(5) optionally polyacrylamide, C13–C14 isoparaffin, and laureth-7;
(6) optionally methyl-p-hydroxybenzoate;
(7) optionally propyl-p-hydroxybenzoate;
(8) optionally phenoxyethanol;
(9) optionally nor-chenodeoxycolic acid;
(10) optionally transcutol; and
(11) optionally water.
16. A pharmaceutical composition consisting essentially of:
(1) one or more pharmacologically active ingredient, wherein the active ingredient is Troxerutine, Nimesulide, or a non steroidal anti-inflammatory drug, wherein said non-steroidal anti-inflammatory drug is Ketoprofen, Diclofenac Sodium, Ibuprofen, Etodolic Acid, Piroxicam, or a combination thereof;
(2) between about 0.01 percent and about 60 percent by weight of a compound of formula I ##STR00009##
wherein n and m are each greater than 18 and are each less than 46 and wherein the compound of the formula I has a molecular weight between about 600 and about 8,000;
(3) phosphatidylcholine;
(4) optionally tocopherol acetate;
(5) optionally polyacrylamide, C13–C14 isoparaffin, and laureth-7;
(6) optionally methyl-p-hydroxybenzoate;
(7) optionally propyl-p-hydroxybenzoate;
(8) optionally phenoxyethanol;
(9) optionally nor-chenodeoxycolic acid;
(10) optionally transcutol;
(11) optionally lactic acid;
(12) optionally ethyl alcohol; and
(13) optionally water.
2. A pharmaceutical composition according to claim 1 with 0.1 percent to 30 per cent by weight of the compound of formula I with n and m>24 and <36 and with the molecular weight between 1,000 and 4,000.
3. A pharmaceutical composition according to claim 1, wherein the composition is in a form selected from the group consisting of creams, emulsions, ointments, lotions, foams, gels, aspersion powders, and transdermal formulations.
4. A method for enhancing absorption of a pharmacologically active ingredient, wherein the method comprises topically applying the pharmaceutical composition claimed in claim 1 to a patient in need thereof wherein the active ingredient is absorbed through derma, cutis, mucosa, rectum, vagina, or urethra.
5. A pharmaceutical composition according to claim 2, wherein the composition is in a form selected from the group consisting of creams, emulsions, ointments, lotions, foams, gels, aspersion powders, and transdermal formulations.
6. The composition according to claim 1, wherein trans-absorption of the active ingredient is increased by up to more than five times its normal value.
7. The composition according to claim 2, wherein trans-absorption of the active ingredient is increased by up to more than five times its normal value.
8. A method for enhancing absorption of a pharmacologically active ingredient, wherein the method comprises topically applying the pharmaceutical composition claimed in claim 2 to a patient in need thereof, wherein the active ingredient is absorbed through derma, cutis, mucosa, rectum, vagina, or urethra.
9. A pharmaceutical composition as claimed in claim 1, wherein trans-absorption of the active ingredient is increased by up to more than ten times its normal value.
10. A pharmaceutical composition as claimed in claim 1, wherein trans-absorption of the active ingredient is increased by up to more than 20 times its normal value.
11. A method as claimed in claim 4, wherein trans-absorption of the active ingredient is increased by up to more than ten times its normal value.
12. A method as claimed in claim 4, wherein trans-absorption of the active ingredient is increased by up to more than 20 times its normal value.
13. A pharmaceutical composition as claimed in claim 1, wherein the active ingredient is troxerutine.
14. A method as claimed in claim 4, wherein the active ingredient is troxerutine.
17. A pharmaceutical composition as claimed in claim 15, wherein the active ingredient is troxerutine.
18. A pharmaceutical composition according to claim 15, wherein the phosphatidlycholine constitutes 0.01 percent to 10 percent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.
19. A pharmaceutical composition according to claim 17, wherein the phosphatidlycholine constitutes 0.01 per cent to 10 percent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.
20. A pharmaceutical composition as claimed in claim 16, wherein the active ingredient is troxerutine.
21. A pharmaceutical composition according to claim 16, wherein the phosphatidlycholine constitutes 0.01 percent to 10 percent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.
22. A pharmaceutical composition according to claim 20, wherein the phosphatidlycholine constitutes 0.01 percent to 10 percent by weight of the pharmaceutical composition, and wherein the compound of the formula I has a molecular weight between 1,000 and about 4,000 with n and m each greater than 24 and each less than 36.
23. The method according to claim 4, wherein the active ingredient is Troxerutine, Nimesulide, Ketopropfen, Etodolic Acid, or a combination thereof.
24. The pharmaceutical composition as claimed in claim 15, wherein the active ingredient is Troxerutine, Nimesulide, Ketopropfen, Etodolic Acid, or a combination thereof.
25. The pharmaceutical composition as claimed in claim 15, wherein the active ingredient is Troxerutine, Nimesulide, Ketopropfen, Etodolic Acid, or a combination thereof.
26. The pharmaceutical composition as claimed in claim 16, wherein the active ingredient is Troxerutine, Nimesulide, Ketopropfen, Etodolic Acid, or a combination thereof.
27. The pharmaceutical composition as claimed in claim 1, wherein phosphatidylcholine is 0.01% to 10% by weight of the pharmaceutical composition.
28. The pharmaceutical composition as claimed in claim 15, wherein the composition consists essentially of the one or more active ingredient, wherein the active ingredient is Troxerutine, Nimesulide, or a non-steroidal anti-inflammatory drug, wherein said nonsteroidal anti-inflammatory drug is Ketoprofen, Diclofenac Sodium, Ibuprofen, Etodolic Acid, Piroxicam, or a combination thereof, the compound formula I, the phosphatidylcholine, and optionally the water.
29. A method according to claim 4, wherein trans-absorption of the active ingredient is increased by up to more than five times its normal value.

The invention described herein refers to pharmaceutical compositions, to the use of compounds as agents with activity for the enhancement of absorption of active ingredients and to specific compounds.

The problems related to percutaneous absorption of active ingredients in topical and transdermal pharmaceutical presentations (drug delivery systems) is known and has been the subject matter of patents [1] Peroutaneous absorption: mechanisms-methodology-drug delivery, 2 Ed., Bronaugh Maiibach, MARCEL DEKKER INC.

Among the most significant examples reported In scientific literature it is possible to mention the enhancing activity of decylmethylsulfoxide in increasing percutaneous absorption of idoxuridine [2] Touitou. E. (1988). Int. J. Pharm. 43:1. The effect of dodecylazacycloheptan-2-one (Laurocapram, Azone) in enhancing absorption of various molecules was Investigated by Stoughton [3] Stoughton, R. B. (1982), Arch. Dermatol. 118: 474 and by Sugibayashi [4] Sugibayashi, K., Hosoya, K. Morimoto, Y., and Higuchi, W. 1. (1985), J. Pharm. Pharmacol. 37: 578.

Substances made available on the market and initially used in fields other than the pharmaceutical sector, subsequently proved to be of remarkable importance also for the pharmaceutical industry. Among these, we can find the Perfluoropolyether class of compounds (PFPE) [5] obtained by polymerization of hexafluoropropene with oxygen activated by UV radiation and subsequent treatment to obtain a cosmetic product [6] as an excipient for preparations used in the manufacture of products with a barrier effect [7].

The following invention consists in the use of PFPE to enhance absorption of pharmacologically active ingredients in topical pharmaceutical presentations and/or in transdermal formulations (drug delivery systems) containing mixtures of at least one active ingredient for the enhancement of absorption.

These compounds, if included in pharmaceutical presentations containing an association or at least one active ingredient, can modify the permeating capacity of the active ingredients through the skin, demonstrating a surprising and unexpected capacity to promote the penetration of the active ingredient.

In accordance with the first aspect of the invention, inclusion of a quantity of PFPE may be applied in traditional topical formulations such as, for example, but not limited to: creams, liquid emulsions, ointments, lotions, microemulsions, foams, gels, aspersion powders; and in transdermal formulations (drug delivery systems).

The term PFPE means molecules with a chemical structure

##STR00002##

Surprisingly, it was found that inclusion of a quantity of PFPE at concentrations between 0.01% w/w and 60% w/w, in topical and/or transdermal (drug delivery systems) formulations, increases the percutaneous absorption of active ingredients by over 5–20 times their normal value, thus enabling improved absorption and optimization of their systemic effects through suitable pharmaceutical presentations.

Comprehension of the invention is facilitated by the description of a number of assessments on the percutaneous absorption of certain formulations containing different active ingredients.

Example A illustrates the increase in permeability by approx. 10 times of a formulation containing Troxerutine and 3% PFPE as compared with that of a reference formulation.

Example B demonstrates the correlation between PFPE concentration and percutaneous absorption of formulations containing Nimesulide and increasing concentrations of PFPE.

Example C contains a comparison of the permeation speed of formulations containing non-steroidal antiinflammatory drugs versus formulations to which 3% PFPE has been added.

Verification of the percutaneous absorption of TROXERUTINE through pig skin using various formulations containing different types of absorption enhancers. In particular, this involved investigation of the release of TROXERUTINE from formulations containing PFPE, Nor-chenodeoxycolic acid and transcutol, versus a reference formulation.

Experimental Section:

Apparatus: Franz Cells (manufacturer: Crown Glass Company Inc., New Jersey)

Franz diffusion cells are one of the main systems used for the investigation of ex-vivo permeation. This study involved the use of three cells each with a 9 mm diameter donor compartment corresponding with a diffusion area of 64 mm2.

The receptor compartment has a capacity of 4.8 ml. The receptor chamber is heated to 37° C.± 1.

Test system: HPLC, Gilson, Mod. 305 with Spectra Physics detector, Spectra 200 Mod.

Formulations:

A B C D
Troxerutine 3 3 3 3
Phosphatidylcholine 7 7 7 7
Tocopherol acetate 0.5 0.5 0.5 0.5
Sepigel 305 4 4 4 4
Methyl-p-hydroxybenzoate 0.15 0.15 0.15 0.15
Propyl-p-hydroxybenzoate 0.05 0.05 0.05 0.05
Phenoxyethanol 1 1 1 1
PFPE 3
Nor-chenodeoxycolic acid 0.4
Transcutol 15
Purified water q.s. to: 100 100 100 100

Preparation of the Skin

The pig skin samples were taken from the internal ear of pigs that had just been sacrificed.

The samples were soaked in buffer solution at pH 7.4 for 24 hours at 4° C.

The sections of connective tissue and muscle were subsequently removed from the skin and the sample was cut into 2×2 cm squares.

The skin samples were stored at −20° C.

HPLC Operating Test Conditions

Column: KP 18, 5 micron Licrospher 100
Mobile phase: 20% acetonitrile 80% phosphate buffer at pH 6.6
Flow: 1 ml/min
Pressure: 1.52 Kpsi
Wavelength: 245 nm
RT: 8.51

Procedure

The pig skin is placed between the donor compartment and the receptor chamber with the external skin surface facing the upper compartment. The test formulation is placed inside the donor compartment.

The receptor chamber is filled with a phosphate buffer solution at pH 7.4 and at intervals between 0.5 and 8 hours, 2 ml of solution are drawn from this chamber. When each sample is taken fresh buffer solution heated to 37° C. is added in order to replenish the initial volume. The samples are then tested using a HPLC method. Each test is repeated three times.

Results

The results on percutaneous absorption are summarized in the table below

mcg of permeated Troxerutine
TIME (h) A B C D
0.5 18.89 13.26 8.29 13.7
1 77.48 43.04 17.17 50.51
2 345.29 102.6 58.19 232.84
4 1,289.11 390.80 229.46 636.68
6 3,999.07 614.95 530 1,053.09
8 12,042 1,090 714.6 1,434.90

Conclusions

Formulations B, C, D did not show any difference in absorption, whilst at the eighth hour, formulation A containing PFPE, demonstrated a degree of absorption that was about 9–10 times greater than that of reference formulation D.

Verification of the absorption of NIMESULIDE through pig skin, using Franz cells, as described in Example A, using various formulations containing different concentrations of PFPE versus a reference formulation.

Formulations:

A B C D
Nimesulide 5 5 5 5
Lactic acid 2 2 2 2
Ethyl alcohol 95° 4 4 4 4
Glycerine 5 5 5 5
PFPE 1.5 3 4.5
Sepigel 305 4 4 4 4
Phosphatidylcholine 2 2 2 2
Methyl-p-hydroxybenzoate 0.15 0.15 0.15 0.15
Propyl-p-hydroxybenzoate 0.05 0.05 0.05 0.05
Purified water q.s. to: 100% 100% 100% 100%

Results

The results on permeability are summarized in the following table

mcg of permeated Nimesulide
TIME (h) A B C D
0.5 0.15 0.16 0.59 0.83
1 0.27 0.39 0.59 1.21
2 0.35 0.72 0.97 1.70
4 0.86 1.14 1.24 1.91
6 1.15 1.54 2.21 2.38
8 1.54 2.24 3.21 3.73
24 3.53 6.00 9.71 9.86

Formulations B, C, D demonstrated an increasing capacity to permeate the skin; this permeating capacity is correlated with the increasing percentage content of PFPE.

Verification of absorption after 8 hours, of topical formulations containing antiinflammatory drugs versus formulations which also contain 3% PFPE, through pig skin, using Franz cells, as described in Example A.

mcg of permeated active ingredient after
Active ingredient 8 hours
contained in the Base formula + 3%
topical formulation Base formula PFPE
Ketoprofen 0.64 5.33
Diclofenac Sodium 1.82 8.66
Ibuprofen 0.21 6.84
Etodolic Acid 0.53 9.93
Piroxicam 1.19 7.94

The invention is characterized by the claims at the end of this description. According to the invention the pharmaceutical compositions contain, apart from one or more active ingredient(s), between 0.01 and 60% w/w of the compounds of formula I

##STR00003##
with n and m>18 and <46 and with molecular weights between ˜600 and ˜8000, as compounds with activity for the enhancement of active ingredient absorption.

Such pharmaceutical compositions may also contain between 0.01 and 20% w/w of Phosphatidylcholine, the compositions preferred are those with 0.1 to 30% w/w of the compounds of formula I with n and m>24 and <36 and with molecular weights between 1000 and 4000 and with 0.1 to 10% w/w of Phosphatidylcholine.

They may also contain other compatible ingredients that are present in the form of creams, emulsions, ointments, lotions, foams, gels and transdermal formulations.

The invention also includes the use of the compounds of formula I

##STR00004##
with n and m>18 and <46, preferably >24 and <36, and with molecular weights between ˜600 and ˜8000, preferably between 1000 and 4000, in pharmaceutical compositions for topical external or internal use for the enhancement of absorption of active ingredients through the derma, cutis, mucosa, rectum, vagina and urethra, with or without Phosphatidylcholine. In particular, such use regards active ingredients that have anabolic, analgesic, androgenic, anesthetic, anorectic, anthelmintic, antiallergic, antiamebic, antiandrogenic, antianginal, antiarrhythmic, antiarteriosclerotic, antiarthritic and antirheumatic, antibacterial, anticholinergic, anticonvulsant, antidepressant, antidiabetic, antidiarrheal, antidiuretic, antiestrogenic, antibiotic, antiglaucoma, antigonatropic, antihistaminic, antihyperlipoproteinemic, antihyperthyroid, antihypertensive, anti-inflammatory, antimalarial, antimigraine, antinauseant, antineoplastic, antiparkinsonian, antiprotozoal, antipruritic, antipsoriatic, antipsychotic, antipyretic, antiseptic, antispasmodic, antithrombotic, antitussive, antiulcer, antiviral, anxiolytic, bronchodilator, CA-blocking or regulating, cardiotonic, stimulating, decongestant, diuretic or enzymatic effect. More specifically, use of this invention regards Troxerutine and Nimesulide and, also

Acyclic ureides such as Acecarbromal, Apronalide, Bomisovalum, Capuride, Carbrormal and Ectylurea;

The use referred to herein increases percutaneous absorption of drugs by over 5 times their normal capacity.

Finally, the invention also regards the compounds belonging to the Perfluoropolyester class of formula I

##STR00005##
with n and m>18 and <46 and with molecular weights between ˜600 and ˜8000, especially those with n and m>24 and <36 with molecular weights between 1000 and 4000, obtained by polymerization of hexafluoropropene

##STR00006##
with UV activated oxygen.

Festo, Norberto

Patent Priority Assignee Title
10039758, Oct 24 2014 KECK GRADUATE INSTITUTE OF APPLIED LIFE SCIENCES Compositions and methods for inhibiting bacterial and viral pathogens
10226496, Sep 26 2013 Topical treatments incorporating Cannabis sp. derived botanical drug product
10406385, Dec 19 2014 Northwestern University Photoluminescent panthenol citrate biomaterials
10485767, Feb 27 2015 10XBIO, LLC Reduction of adipose tissue
10568845, Aug 24 2001 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system with fentanyl or related substances
10583093, Aug 24 2001 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system with fentanyl or related substances
10610518, Apr 24 2018 Allergan, Inc. Presbyopia treatments
10653736, Sep 26 2013 Topical treatments incorporating cannabis sp. derived botanical drug product
10702469, Jun 08 2007 Troikaa Pharmaceuticals Ltd Non-aqueous topical solution of diclofenac and process for preparing the same
10702571, Dec 03 2015 The University of North Carolina at Pembroke Materials for cathepsin B enhancement and methods of use
10940122, Aug 24 2001 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system with fentanyl or related substances
11065210, Feb 27 2015 10XBIO, LLC Reduction of adipose tissue
11166971, Mar 23 2020 Methods of treating COVID-19 infection
11253534, Mar 23 2020 Method of preventing COVID-19 infection
11278520, Mar 31 2020 PROGENABIOME, LLC Method of preventing COVID-19 infection
11285134, Apr 24 2018 Allergan, Inc. Presbyopia treatments
11534470, Sep 26 2013 Topical treatments incorporating Cannabis sp. derived botanical drug product
11744866, Mar 18 2020 Methods of preventing and treating COVID-19 infection with probiotics
11872242, Mar 23 2020 Methods of preventing and treating COVID-19 infection
7878978, Mar 19 2004 University of Pittsburgh - Of the Commonwealth System of Higher Education Use of relaxin to increase arterial compliance
8263581, Jul 03 2009 JDP THERAPEUTICS, INC Non-sedating antihistamine injection formulations and methods of use thereof
8314083, Jul 03 2009 JDP THERAPEUTICS, INC Non-sedating antihistamine injection formulations and methods of use thereof
8513259, Jul 03 2009 JDP Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
8602998, Mar 18 2004 University of Pittsburgh - Of the Commonwealth System of Higher Education Use of relaxin to increase arterial compliance
9095563, Sep 26 2013 Topical treatments incorporating Cannabis sp. derived botanical drug product
9119771, Jul 03 2009 JDP Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
9161902, Jul 03 2009 JDP Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
9180090, Jul 03 2009 JDP Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
9351945, Feb 27 2015 10XBIO, LLC Reduction of adipose tissue
9687455, Aug 14 2014 Sodium tetradecyl sulfate formulations for treatment of adipose tissue
9844520, Feb 27 2015 10XBIO, LLC Reduction of adipose tissue
Patent Priority Assignee Title
5304334, Apr 28 1992 Estee Lauder, Inc Method of preparing a multiphase composition
5376359, Jul 07 1992 Glaxo, Inc.; GLAXO, INC A CORP OF NORTH CAROLINA Method of stabilizing aerosol formulations
5686102, Jun 26 1992 Lancaster Group GmbH Pharmacological composition for topical administration
EP390206,
EP723775,
JP6242922,
//
Executed onAssignorAssigneeConveyanceFrameReelDoc
Feb 16 2000Inpharma S.A.(assignment on the face of the patent)
Sep 19 2000FESTO, NORBERTOINPHARMA S A ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0112290627 pdf
Date Maintenance Fee Events
Sep 11 2009M2551: Payment of Maintenance Fee, 4th Yr, Small Entity.
Sep 11 2013M2552: Payment of Maintenance Fee, 8th Yr, Small Entity.
Nov 20 2017REM: Maintenance Fee Reminder Mailed.
May 07 2018EXP: Patent Expired for Failure to Pay Maintenance Fees.


Date Maintenance Schedule
Apr 11 20094 years fee payment window open
Oct 11 20096 months grace period start (w surcharge)
Apr 11 2010patent expiry (for year 4)
Apr 11 20122 years to revive unintentionally abandoned end. (for year 4)
Apr 11 20138 years fee payment window open
Oct 11 20136 months grace period start (w surcharge)
Apr 11 2014patent expiry (for year 8)
Apr 11 20162 years to revive unintentionally abandoned end. (for year 8)
Apr 11 201712 years fee payment window open
Oct 11 20176 months grace period start (w surcharge)
Apr 11 2018patent expiry (for year 12)
Apr 11 20202 years to revive unintentionally abandoned end. (for year 12)